Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.57 |
| ▸ | PRMT6 | Q96LA8 | 12/20 | 0.56 |
| ▸ | CARM1 | Q86X55 | 11/20 | 0.56 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7737516 | 0.84 | HTR7 (0.58) | KDM1APRMT6CARM1HTR7MEN1 | |
| SCHEMBL4932045 | 0.80 | DPP7 (0.58) | KDM1APRMT6CARM1HTR7MEN1 | |
| SCHEMBL29448595 | 0.80 | PRMT6 (0.71) | PRMT6CARM1TMEM97SIGMAR1PRMT8 | |
| SCHEMBL19047887 | 0.79 | KDM1A (0.58) | KDM1AHTR7MEN1KMT2AALDH1A1 | |
| SCHEMBL8673780 | 0.79 | POLB (0.59) | MEN1KMT2AALDH1A1MAPTSIGMAR1 | |
| Hydrochloric Acid SCHEMBL5753957 | 0.79 | DPP7 (0.56) | KDM1APRMT6CARM1HTR7MEN1 | |
| SCHEMBL19047974 | 0.78 | KDM1A (0.59) | KDM1AHTR7KMT2AALDH1A1MAPT | |
| SCHEMBL19047889 | 0.78 | KDM1A (0.59) | KDM1AALDH1A1MAPTHRH3 | |
| Hydrochloric Acid SCHEMBL11093613 | 0.77 | POLB (0.58) | MEN1KMT2AALDH1A1SIGMAR1HRH3 | |
| Hydrochloric Acid SCHEMBL11614221 | 0.77 | DPP7 (0.54) | KDM1APRMT6CARM1HTR7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3397616-B1 | LSD1 INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2020-06-10 | — | — | EP | disclosed |
| US-10233152-B2 | LSD1 inhibitors | Mirati Therapeutics, Inc. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180127369-A1 | LSD1 Inhibitors | Mirati Therapeutics, Inc. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233152-B2 | LSD1 inhibitors | KDM1B, KDM1A, KDM3A | KDM1A 2/4885PRMT6 70/4885CARM1 56/4885 |
| US-20180127369-A1 | LSD1 Inhibitors | KDM1B, KDM1A, KDM3A | KDM1A 2/4885PRMT6 70/4885CARM1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.